Menin Inhibitor Mechanism and Patient Selection Strategies

Dr. Patel explains the biological rationale for targeting the menin-KMT2A pathway in NPM1-mutated AML, describing breakthrough discoveries demonstrating menin's role in leukemogenesis for NPM1-mutated and KMT2A-rearranged acute leukemia. Menin protein represents the therapeutically vulnerable target, with complex disruption providing viable treatment strategies supported by preclinical work leading to clinical development of an entire menin inhibitor drug class.

The targeted therapy appeal stems from its differentiation-inducing mechanism rather than cytotoxic cell killing. For R/R acute leukemia patients who may not be healthy or fit enough for intensive traditional cytotoxic chemotherapy, targeted therapies including menin inhibitors, IDH inhibitors, and FLT3 inhibitors enable continued effective treatment. As differentiating agents, menin inhibitors require careful monitoring for adverse events, particularly differentiation syndrome risk, but represent oral, fairly well-tolerated therapies.

Dr. Arana Yi emphasizes patient education regarding menin inhibitors' different mechanism compared to traditional chemotherapy, promoting blast differentiation rather than cell killing. Responses may take longer than conventional leukemia cell killing approaches but offer better tolerability for patients unsuitable for transplant or intensive chemotherapy due to multiple comorbidities. Key monitoring focuses on differentiation syndrome through close patient surveillance for blood count changes, fluid retention, weight gain, and shortness of breath symptoms, with early detection enabling appropriate management through closer monitoring, telemetry beds, oxygen treatment, and steroid therapy for rapid symptom improvement while continuing therapy until desired responses are achieved.